UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048987
Receipt number R000055807
Scientific Title Clinical study of whitening cream
Date of disclosure of the study information 2022/10/01
Last modified on 2024/04/02 11:47:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical study of whitening cream

Acronym

Clinical study of whitening cream

Scientific Title

Clinical study of whitening cream

Scientific Title:Acronym

Clinical study of whitening cream

Region

Japan


Condition

Condition

Pigmentation

Classification by specialty

Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Verification of whitening effect and safety on thyroid function through 12 months of continuous use of the test product.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visual evaluation

Key secondary outcomes

Blood tests (T3, T4, TSH levels)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Apply the test product to the entire face twice a day (morning and night) for 12 months.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

49 years-old >=

Gender

Female

Key inclusion criteria

Persons with pigmentation on the face. (melasma, lentigo senilis, ephelis, etc.)

Key exclusion criteria

1. Persons with a smoking habit.
2. Persons with a history of serious illness within the past 5 years.(pigmentation and thyroid function)
3. Persons who currently have thyroid dysfunction.
4. Persons who have received treatment such as immunosuppression within the past 3 months.
5. Persons who may have allergic reactions to cosmetic ingredients.
6. Persons with chronic skin diseases such as atopic dermatitis.
7. Persons at risk of showing hay fever symptoms during the study period.
8. Persons with scars, warts, pimples, permanent makeup, burns, etc. on the face that would affect the evaluation measurement.
9. Persons receiving hormone replacement therapy.
10. Persons who have experience in cosmetic medicine on the face.
11. Persons who have difficulty maintaining lifestyle habits.(eating, exercising, sleeping, skin care, etc.)
12. Persons who are pregnant, lactating, may be pregnant, or wish to become pregnant.
13. Persons who are participating in other clinical study at the start of this study.
14. Individuals or family members who work for a company that develops, manufactures, or sells cosmetics.

Target sample size

15


Research contact person

Name of lead principal investigator

1st name Kazuhiro
Middle name
Last name Iga

Organization

Sansho Pharmaceutical Co.,Ltd.

Division name

Raw Material Development Department

Zip code

816-8550

Address

2-26-7,Oike,Onojo-city,Fukuoka

TEL

092-503-1183

Email

iga@dermed.jp


Public contact

Name of contact person

1st name Kazuhiro
Middle name
Last name Iga

Organization

Sansho Pharmaceutical Co.,Ltd.

Division name

Raw Material Development Department

Zip code

816-8550

Address

2-26-7,Oike,Onojo-city,Fukuoka

TEL

092-503-1183

Homepage URL


Email

iga@dermed.jp


Sponsor or person

Institute

Sansho Pharmaceutical Co.,Ltd.

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Tokyo Saiseikai Central Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tokyo Saiseikai Central Hospital Clinical Research Ethics Review Committee

Address

1-4-17 Mita, Minato-ku, Tokyo

Tel

03-3451-8211

Email

tikenjimu@saichu.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京都済生会中央病院(東京都)


Other administrative information

Date of disclosure of the study information

2022 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

19

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 07 Month 07 Day

Date of IRB

2022 Year 08 Month 17 Day

Anticipated trial start date

2022 Year 10 Month 01 Day

Last follow-up date

2023 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2024 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2022 Year 09 Month 21 Day

Last modified on

2024 Year 04 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055807


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name